4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Atossa Therapeutics, Inc. (ATOS) operates in the Biotechnology industry and is headquartered in Seattle, United States with about 16 employees. Its market capitalization is roughly $23 million. In the fiscal year ended 2025-12-31, ATOS reported $0M in revenue and ($35M) in net income.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($37M) | ($28M) | ($31M) | ($28M) |
| Net Income | ($35M) | ($26M) | ($30M) | ($27M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($10M) | ($11M) | ($9M) | ($9M) | ($7M) | — |
| Net Income | ($10M) | ($11M) | ($9M) | ($8M) | ($7M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $48M | $76M | $96M | $124M | — |
| Total Liabilities | $8M | $5M | $5M | $6M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ATOS viewer.
About TickerBase · Data methodology & sources